GlassScriptPhysician profile
Mark T Claus
NPI 1518910686
$13,180.93
in general payments reported to CMS, 2019-2025
38 companies · $2,904 in 2025
The $2,904 reported for 2025 was more than what 78% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $769 · 2020: $1,175 · 2021: $2,005 · 2022: $1,920 · 2023: $1,954 · 2024: $2,454 · 2025: $2,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,165 · Education: $137 · Gift: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,165.12 |
| Education | $137.45 |
| Gift | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,683.17 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,886.75 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,105.32 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $805.61 | 2019-2025 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $399.75 | 2019-2023 | Airduo Digihaler |
| Novartis Pharmaceuticals Corporation | $382.27 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $367.94 | 2020-2025 | Cuvitru, Eohilia, Hyqvia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.48 | 2019-2023 | Spiriva Respimat |
| Amgen INC. | $290.54 | 2021-2025 | Tezspire |
| Blueprint Medicines Corporation | $268.64 | 2023-2025 | Ayvakit |
| Genentech USA, INC. | $261.39 | 2019-2025 | Xolair |
| Octapharma USA, INC. | $245.79 | 2019-2025 | Cutaquig |
| Pharming Healthcare, INC. | $242.26 | 2020-2025 | Ruconest |
| Kaleo, INC. | $226.18 | 2019-2023 | Auvi-Q |
| Grifols USA, LLC | $209.58 | 2021-2025 | Prolastin-C Liquid, Xembify |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $195.99 | 2019-2025 | |
| Csl Behring | $191.58 | 2019-2025 | Hizentra, Haegarda |
| Covis Pharma Gmbh | $114.14 | 2021-2023 | |
| Gc Biopharma USA, INC. | $111.76 | 2025 | Alyglo |
| Abbvie INC. | $106.05 | 2022-2023 | Rinvoq |
| Aimmune Therapeutics, INC. | $101.25 | 2021-2023 | |
| Biocryst US Sales Co., LLC | $96.66 | 2022-2025 | Orladeyo |
| Lilly USA, LLC | $90.73 | 2025 | Ebglyss |
| Alk-Abello, INC | $77.24 | 2019-2020 | |
| Mylan Specialty L.P. | $56.80 | 2021 | |
| Verona Pharma, INC. | $51.42 | 2025 | Ohtuvayre |
| Incyte Corporation | $49.15 | 2022 | |
| Organon LLC | $45.46 | 2025 | Vtama |
| X4 Pharmaceuticals, INC. | $34.15 | 2025 | Xolremdi |
| Ars Pharmaceuticals Operations, INC. | $27.85 | 2025 | Neffy |
| Invivyd INC | $21.07 | 2025 | Pemgarda |
| Merck Sharp & Dohme LLC | $18.32 | 2023 | |
| Azurity Pharmaceuticals, INC. | $17.28 | 2025 | Alvesco |
| Biohaven Pharmaceuticals, INC. | $16.81 | 2021 | |
| Hikma Pharmaceuticals USA | $15.33 | 2023 | Ryaltris |
| Eyevance Pharmaceuticals LLC | $12.63 | 2021 | |
| Shire North American Group INC | $12.59 | 2019 | |
| Purelife, LLC | $10.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Claus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.